


Docket
Number

PH-7268

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL983150230US
Express Mail Label Number

October 12, 2004
Date of Deposit



**PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN THE APPLICATION OF: Percy Carter

CASE NO.: PH-7268

SERIAL NO.: 10/027,505

GROUP ART UNIT: 1624

FILED: 12/20/01

EXAMINER: Rao, Deepak

FOR: DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Mailstop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).


Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: October 12, 2004

Respectfully submitted,

Mary Van

Mary K. VanAtten
Attorney for Applicant
Reg. No. 39,408
Phone No. (609) 252-4379



Docket Number	PH-7268
FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EL983150230US Express Mail Label Number	October 12, 2004 Date of Deposit

**PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN THE APPLICATION OF: Percy Carter

CASE NO.: PH-7268

SERIAL NO.: 10/027,505

GROUP ART UNIT: 1624

FILED: 12/20/01

EXAMINER: Rao, Deepak

FOR: DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Mailstop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: October 12, 2004


Respectfully submitted,

Mary VanAtten

Mary K. VanAtten
Attorney for Applicant
Reg. No. 39,408
Phone No. (609) 252-4379

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PH-7268
APPLICATION NO.
10/027,505
APPLICANT
Carter et al.
FILING DATE
12/20/01

Group

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AA	WO 99/46991	9/23/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AB						<input type="checkbox"/>	<input type="checkbox"/>
	AC						<input type="checkbox"/>	<input type="checkbox"/>
	AD						<input type="checkbox"/>	<input type="checkbox"/>
	AE						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)


AF	K. J. Kennedy et al., "Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1 α and monocyte chemoattractant protein-1", Journal of Neuroimmunology, Vol. 92, pp. 98-108, 1998.
AG	Fife et al., "CC Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis", J. Exp. Med., Vol. 192, No.6, pp. 899-905, 2000.
AH	Izikson et al., "Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the CC Chemokine Receptor (CCR)2", J. Exp. Med., Vol. 192, No. 7, pp. 1075-1080, 2000.
AI	Tesch et al., "Monocyte Chemoattractant Protein 1-dependent Leukocytic Infiltrates Are Responsible for Autoimmune Disease in MRL-FAS ^{lpr} Mice", J. Exp. Med., Vol. 190, No. 12, pp.1813-1824, 1999.
AJ	Andres et al., "Mice with a Selective Deletion of the CC Chemokine Receptors 5 or 2 Are Protected from Dextran Sodium Sulfate-Mediated Colitis: Lack of CC Chemokine Receptor 5 Expression Results in a NK1.1 ⁺ Lymphocyte-Associated Th2-Type Immune Response in the Intestine," The Journal of Immunology, Vol. 164, pp. 6303-6312, 2000.
AK	Jones et al., "Potential Role of Monocyte Chemoattractant Protein 1/JE in Monocyte/Macrophage-Dependent IgA Immune Complex Alveolitis in the Rat ¹ ", The Journal of Immunology, Vol. 149, No. 6, pp. 2147-2154, 1992.
AL	Reinecker et al., "Monocyte-Chemoattractant Protein 1 Gene Expression in Intestinal Epithelial Cells and Inflammatory Bowel Disease Mucosa", Gastroenterology, Vol. 108, No. 1, pp. 40-50, 1995.
AM	Grimm et al., "Enhanced Expression and Production of Monocyte Chemoattractant Protein-1 in Inflammatory Bowel Disease Mucosa", Journal of Leukocyte Biology, Vol. 59, pp. 804-812, 1996.
AN	Russell et al., "Early and Persistent Induction of Monocyte Chemoattractant Protein 1 in Rat Cardiac Allografts", Proc. Natl. Acad. Sci., Vol. 90, pp. 6086-6090, 1993.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION



ATTY. DOCKET NO.
PH-7268
APPLICATION NO.
10/027,505
APPLICANT
Carter et al.
FILING DATE
12/20/01

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AO	Antoniades et al., "Expression of Monocyte Chemoattractant Protein 1 mRNA in Human Idiopathic Pulmonary Fibrosis", Proc. Natl. Acad. Sci., Vol. 89, pp. 5371-5375, 1992.
AP	Deleuran et al., "Localization of Monocyte Chemotactic and Activating Factor (MCAF/MCP-1) in Psoriasis", Journal of Dermatological Science, Vol. 13, pp. 228-236, 1996.
AQ	Gillitzer et al., "MCP-1 in mRNA Expression in Basal Keratinocytes of Psoriatic Lesions", The Journal of Investigative Dermatology, Vol. 101, No. 2, pp. 127-131, 1993.
AR	Connor et al., "Change in Coreceptor Use Correlates with Disease Progression in HIV-1-Infected Individuals", J. Exp. Med., Vol. 185, No. 4, pp. 621-628, 1997.
AS	Smith et al., "Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression", Science, Vol. 277, pp. 959-964, 1997.
AT	
AU	
AV	
AW	
AX	
AY	
AZ	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.